SEC Comment Letter for Lantern Pharma Inc. (LTRN) (CIK 0001763950) (LTRN) — Jun 3, 2024
Lantern Pharma Inc. (LTRN) (CIK 0001763950)
Date: June 3, 2024 · CIK: 0001763950 · Accession: 0000000000-24-006316
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-279718
Letter
United States securities and exchange commission logo June 3, 2024 Panna Sharma Chief Executive Officer Lantern Pharma Inc. 1920 McKinney Avenue, 7th Floor Dallas, TX 75201 Re:Lantern Pharma Inc. Registration Statement on Form S-3 Filed May 24, 2024 File No. 333-279718 Dear Panna Sharma: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Daniel K. Donahue, Esq.
Show Raw Text
United States securities and exchange commission logo
June 3, 2024
Panna Sharma
Chief Executive Officer
Lantern Pharma Inc.
1920 McKinney Avenue, 7th Floor
Dallas, TX 75201
Re:Lantern Pharma Inc.
Registration Statement on Form S-3
Filed May 24, 2024
File No. 333-279718
Dear Panna Sharma:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Daniel K. Donahue, Esq.